Shares of Mead Johnson Nutrition are slumping 2.24% to $68.56 on Wednesday.
Both its profit and revenue are anticipated to decline year-over-year.
For the latest quarter, Wall Street is estimating earnings of 73 cents a share on revenue of $966.05 million.
During the same quarter the year prior, the company earned 92 cents a share on revenue of $1.09 billion.
Analysts believe China's slowing economy will dampen the company's sales and margins.
Separately, TheStreet Ratings currently has a Buy rating on the stock with a letter grade of B-.
The company's strengths can be seen in multiple areas, such as its notable return on equity and expanding profit margins.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: MJN